Evidence map›Paper›PMID 34462490›Full record

ArticleScientific reports2021

Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.

Natalia Palazón-Carrión, Carlos Jiménez-Cortegana, M Luisa Sánchez-León, Fernando Henao-Carrasco, Esteban Nogales-Fernández, Massimo Chiesa, Rosalía Caballero, Federico Rojo, María-Adoración Nieto-García, Víctor Sánchez-Margalet and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Natalia Palazón-CarriónClinical Oncology Department, Virgen Macarena University Hospital, Seville, Spain.
Carlos Jiménez-CorteganaDepartment of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, University of Seville, Seville, Spain.
M Luisa Sánchez-LeónClinical Oncology Department, Virgen Macarena University Hospital, Seville, Spain.
Fernando Henao-CarrascoClinical Oncology Department, Virgen Macarena University Hospital, Seville, Spain.
Esteban Nogales-FernándezClinical Oncology Department, Virgen Macarena University Hospital, Seville, Spain.
Massimo ChiesaGEICAM (Spanish Breast Cancer Research Group), Madrid, Spain.
Rosalía CaballeroGEICAM (Spanish Breast Cancer Research Group), Madrid, Spain.
Federico RojoPathology Department, IIS-Fundación Jimenez Diaz-CIBERONC, Madrid, Spain.
María-Adoración Nieto-GarcíaDepartment of Preventive Medicine and Public Health, Faculty of Medicine, University of Seville, Seville, Spain.
Víctor Sánchez-MargaletDepartment of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, University of Seville, Seville, Spain. margalet@us.es.ORCID https://orcid.org/0000-0001-8638-8680
Luis de la Cruz-MerinoClinical Oncology Department, Virgen Macarena University Hospital, Seville, Spain. ldelacruzmerino@gmail.com.ORCID https://orcid.org/0000-0002-5333-0535
Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34462490
PMCPMC8405810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.